Home | GSK US
Press releases. October 24 2024 GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S. October 24 2024 New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease. October 16 2024 ViiV Healthcare shows more ...
Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products. Tel: 800-745-2967.
Products | GSK US
Products. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
Company | GSK US
By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people by the end of the decade. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive. …
At a glance | GSK US
At a glance. Getting Ahead Together means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies.
Press releases | GSK US
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Update - GSK Consumer Healthcare | GSK US
Jan 15, 2022 · GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of £50 billion comprising £41.7 billion in cash and £8.3 billion in ...
Locations | GSK US
Locations | GSK US ... tbc
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...